Pharmacovigilance in radiopharmaceuticals

被引：5

作者：

Kumar, Rishi ^{[1
]}

Kalaiselvan, Vivekanandan ^{[2
]}

Kumar, Rakesh ^{[1
]}

Verma, Ravendra ^{[2
]}

Singh, Gyanendra Nath ^{[2
]}

机构：

[1] Indian Pharmacopoeia Commiss, Natl Coordinat Ctr, Pharmacovigilance Programme India, Pharmacovigilance Div, Ghaziabad, Uttar Pradesh, India

[2] Indian Pharmacopoeia Commiss, Pharmacovigilance Div, Ghaziabad, Uttar Pradesh, India

来源：

INDIAN JOURNAL OF NUCLEAR MEDICINE | 2016年 / 31卷 / 02期

关键词：

Adverse drug reactions; pharmacovigilance; radiopharmaceuticals;

D O I：

10.4103/0972-3919.178252

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Indian Pharmacopoeia Commission is Committed for maintaining the standards of drugs including Radiopharmaceuticals (RPs) by publishing Indian Pharmacopoeia. These RPs are being used in India for diagnostic or therapeutic purpose. RPs though contain relatively small quantities of active ingredient and administered in small volumes could cause some adverse reactions to the patients. The objective of presenting this article is to introduce the system of adverse drug reaction reporting to the nuclear medicine fraternity who are dealing with RPs.

引用

页码：89 / 92

页数：4

共 10 条

[1]

[Anonymous], 2014, IND PHARM 2014

[2]

[Anonymous], 2015, ADD 2015 IND PHARM 2

[3]

Arara D, 2008, INDIAN J PHARMACOL, V40, pS13

[4]

Kalaiselvan V., 2014, IND J PHARM PRACT, V7, P19